As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting